Loading…
Indivior Pharmaceuticals, Inc. is projected to rise to $60.30 by 2027, a +49% move from its current price of $40.50. INDV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $39.89 | $40.53 | $41.18 | +0.08% |
| Jul 13 | $39.66 | $40.56 | $41.49 | +0.16% |
| Jul 14 | $39.49 | $40.60 | $41.74 | +0.24% |
| Jul 15 | $39.35 | $40.63 | $41.95 | +0.32% |
| Jul 16 | $39.23 | $40.66 | $42.14 | +0.40% |
| Jul 17 | $39.13 | $40.69 | $42.32 | +0.48% |
| Jul 18 | $39.04 | $40.73 | $42.48 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $39.04 | $40.73 | $42.48 | +0.56% |
| Week 2 | $38.58 | $40.95 | $43.47 | +1.11% |
| Week 3 | $38.27 | $41.18 | $44.31 | +1.68% |
| Week 4 | $38.05 | $41.41 | $45.06 | +2.24% |
| Week 5 | $37.88 | $41.64 | $45.76 | +2.81% |
| Week 6 | $37.75 | $41.87 | $46.44 | +3.38% |
| Week 7 | $37.65 | $42.10 | $47.08 | +3.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Indivior Pharmaceuticals, Inc. is a healthcare company that develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.
The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc. (INDV) is a healthcare stock currently trading with a price of $41.47. Its market cap is $4.9B and its rank is 1376, reflecting its size within the market.
The asset operates in the Healthcare category and is part of the pharmaceutical sector focused on buprenorphine-based therapies for opioid use disorder. The 2026 forecast shows an average price of $41.47, with the potential to rise to $58.81 at the high end, illustrating a path toward meaningful long‑term upside that extends to $1,442.21 as the max in 2050. These figures point to a bullish longer‑term outlook, though individual results may vary and are not guaranteed.
A major floor 28.9% below — a decisive break under it would weaken the trend.
The nearest floor, 16.8% below — buyers have tended to step in here.
The nearest ceiling, 3.3% above — a clean break opens room to run.
A major ceiling 15.6% above — clearing it would confirm fresh momentum.
Key INDV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INDV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.70 | Sell | $40.72 | Sell |
| MA 10 | $40.77 | Sell | $40.53 | Sell |
| MA 20 | $39.90 | Buy | $39.89 | Buy |
| MA 50 | $38.43 | Buy | $38.15 | Buy |
| MA 100 | $35.15 | Buy | $36.11 | Buy |
| MA 200 | $33.21 | Buy | $32.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.47 | Neutral |
| Stoch RSI (14) | 7.67 | Buy |
| CCI (20) | 33.93 | Neutral |
| Williams %R (14) | -37.89 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 1.35 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 62.11 | Neutral |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 2.07 | Buy |
| Ultimate (7,14,28) | 51.41 | Neutral |
| Momentum (10) | -0.79 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 41.02 | Sell |
| ADX (14) | 22.59 | Buy |
| ATR (14) | 0.55 | Info |
The 30‑day technical picture is bullish. The RSI(14) sits at 70, indicating strong near‑term momentum, while the 50‑day simple moving average stands at $36.71 and the 200‑day simple moving average at $32.26. The stock’s near‑term outlook is supported by a positive sentiment and a price structure that favors upside above the 50‑day average.
In the last 30 days, the price traded from a low of $36.50 to a high of $47.12, with support at $33.71 and resistance at $41.47.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.78 | $40.50 | $57.38 | 0% | Neutral | |
| $49.39 | $60.30 | $76.98 | +49% | Bullish | |
| $66.18 | $82.33 | $107.94 | +103% | Bullish | |
| $77.24 | $97.56 | $130.64 | +141% | Bullish | |
| $82.44 | $105.54 | $143.86 | +161% | Bullish | |
| $99.12 | $128.44 | $177.85 | +217% | Bullish | |
| $111.31 | $145.86 | $204.85 | +260% | Bullish | |
| $128.69 | $170.42 | $242.44 | +321% | Bullish | |
| $163.42 | $218.57 | $314.64 | +440% | Bullish | |
| $179.91 | $242.90 | $353.56 | +500% | Bullish | |
| $305.99 | $430.88 | $657.26 | +964% | Bullish | |
| $592.33 | $894.56 | $1,462.70 | +21.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.78 | $40.50 | $49.57 | +0.00% |
| August 2026 | $37.19 | $43.54 | $52.08 | +7.50% |
| September 2026 | $37.01 | $43.53 | $52.48 | -0.01% |
| October 2026 | $37.33 | $44.09 | $53.49 | +1.27% |
| November 2026 | $38.73 | $45.90 | $56.00 | +4.12% |
| December 2026 | $39.36 | $46.79 | $57.38 | +1.95% |
Click any year to see its month-by-month INDV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect INDV to range from $28.78 to $57.38 through 2026. The $40.50 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The INDV price prediction for 2027 points to an average of $60.30 (low $49.39, high $76.98) — a potential gain of +49% on today's $40.50. Buyers look set to stay in control over this stretch.
In 2028, INDV is projected to trade between $66.18 and $107.94, averaging $82.33 — a potential gain of +103% from today's $40.50. That is up +37% on the projected 2027 average. Momentum favours further upside here.
Indivior Pharmaceuticals, Inc.'s 2029 outlook centres on $97.56, within a $77.24 to $130.64 range. That is up +19% on the projected 2028 average. That marks a +141% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, INDV could reach as high as $143.86, with a base case around $105.54 and support toward $82.44 — roughly +161% from $40.50. Momentum favours further upside here.
Expect INDV to range from $99.12 to $177.85 through 2031. The $128.44 average target implies a +217% move from current prices. That is up +22% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The INDV price prediction for 2032 points to an average of $145.86 (low $111.31, high $204.85) — a potential gain of +260% on today's $40.50. Momentum favours further upside here.
In 2033, INDV is projected to trade between $128.69 and $242.44, averaging $170.42 — a potential gain of +321% from today's $40.50. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Indivior Pharmaceuticals, Inc.'s 2034 outlook centres on $218.57, within a $163.42 to $314.64 range. That is up +28% on the projected 2033 average. That marks a +440% change versus current levels. Momentum favours further upside here.
By 2035, INDV could reach as high as $353.56, with a base case around $242.90 and support toward $179.91 — roughly +500% from $40.50. Buyers look set to stay in control over this stretch.
Expect INDV to range from $305.99 to $657.26 through 2040. The $430.88 average target implies a +964% move from current prices. That is up +77% on the projected 2035 average. Momentum favours further upside here.
The INDV price prediction for 2050 points to an average of $894.56 (low $592.33, high $1,462.70) — a potential gain of +21.1x on today's $40.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in INDV today (≈ 24.691358 INDV) could be worth
$22,087.94
+$21,087.94 (+2109%) by 2050 · US Dollar
Based on the average projected INDV price of $894.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INDVwould be worth at today's price.
$1,000 invested in INDV on Jul 10, 2025 (≈ 65.061809 INDV) would be worth
$2,635
+$1,635 (+163.5%) today · 2.64× · US Dollar
Based on a INDV entry price of $15.37 vs. today's $40.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $39.8 | $1,017.59 | +1.8% |
| 1 month ago | $38.09 | $1,063.27 | +6.3% |
| 3 months ago | $30.54 | $1,326.13 | +32.6% |
| 6 months ago | $34.56 | $1,171.87 | +17.2% |
| 1 year ago | $15.37 | $2,635 | +163.5% |
| All time (5.0y) ago | $11 | $3,681.82 | +268.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INDV forecast.
Our base-case forecast reaches $81.00 around 2028.
Implied market cap at $81.00: $9.57B
Looking further out, the published year‑by‑year forecast shows a multi‑year bullish path. By 2030 the average price is expected to be $107.84 with a max of $147.74 and a min of $83.91, corresponding to an estimated ROI of 160% and a bullish sentiment. The trajectory continues with a 2040 average of $432.46 and a max of $664.45 (ROI 942.8%), and a 2050 average of $874.52 with a max of $1,442.21 (ROI 2008.8%), all signaling ongoing upside.
These figures reflect estimates and are not guarantees; actual results may vary and depend on multiple factors including market conditions and business developments.
Tap a question to reveal the answer.
Avg $107.84; Min $83.91; Max $147.74; ROI 160%; Sentiment BULLISH.
The forecast shows a shift to bullish sentiment from 2027 onward, with rising average prices (e.g., $62.77 in 2027 and $107.84 in 2030) and notable upside, though these are estimates and not guarantees.
Yes. The forecast's 2050 max price is $1,442.21, indicating the possibility of topping $1,000.
Current price is $41.47 and market cap is $4.9B, with a rank of 1376.
RSI(14) is 70; SMA(50) is $36.71; SMA(200) is $32.26; support is $33.71 and resistance is $41.47; the 30‑day range is $36.50 to $47.12.
Indivior Pharmaceuticals, Inc. Community Discussion
0Share your Indivior Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.